Insulet (PODD) EPS (Diluted) Growth (3y) (2019 - 2026)
Insulet (PODD) EPS (Diluted) Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -6.43% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 7.66% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 3.09% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 62.91% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 63.42% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 29.56% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 30.57% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 56.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.35% |
| Dec 31, 2025 | 79.85% |
| Sep 30, 2025 | 164.72% |
| Jun 30, 2025 | 38.05% |
| Mar 31, 2025 | 6.37% |
| Dec 31, 2024 | 47.37% |
| Sep 30, 2024 | 79.57% |
| Jun 30, 2024 | 106.59% |
| Dec 31, 2023 | 95.01% |
| Sep 30, 2023 | 59.54% |
| Jun 30, 2023 | 21.02% |
| Mar 31, 2023 | 130.00% |
| Dec 31, 2022 | 44.71% |
| Sep 30, 2022 | -98.63% |
| Jun 30, 2022 | -189.10% |
| Mar 31, 2022 | 76.84% |
| Dec 31, 2021 | 37.92% |
| Sep 30, 2021 | 88.24% |
| Jun 30, 2021 | -135.38% |
| Dec 31, 2019 | 413.16% |